Table 4. Functional clustering of differentially expressed genes between ICSI BCB+ and ICSI BCB−; mICSI BCB− and ICSI BCB−; and mICSI BCB− and ICSI BCB+ blastocysts following unpaired t-tests, with FC > 2 (abs) and significance of p < 0.01.
| Clustering of differentially expressed genes (T-Test, p value < 0.01, abs. FC > 2) | Top Diseases and Functions | Network(s) | Predicted upstream Regulator | Molecule Type | Regulation | Activation z-score (abs. Fold-change > 1.5) | p-value of overlap (p < 0.05) |
|---|---|---|---|---|---|---|---|
| ICSI BCB− vs ICSI BCB+blastocysts | |||||||
| BAG3, CCBL1, CGREF1, CREM, EDN1, FAM73A, JUN, KLF5, OXNAD1, PITPNB, SMN1/SMN2 | Cellular Assembly and Organization, Cellular Function and Maintenance, Cell Death and Survival | Supp. Figs 7, 8, 9, 12, 17 and 18 | CREB1 | transcription regulator | Activation | 2.617 | 1.57E-03 |
| BCAT2, EDN1, EPHX2, JUN, MXD3, PGK1, PRDX2, SMTN, SPINT1, UCK1 | Cancer, Cellular Movement, Organismal Development | Supp. Figs 7, 8 and 18 | ERBB2 | kinase | Activation | 2.236 | 1.51E-02 |
| EDN1, JUN, KLF5, SRF | Inflammatory Disease, Inflammatory Response, Organismal Injury and Abnormalities | Supp. Figs 7, 12 and 18 | lysophosphatidic acid | chemical - other | Activation | 1.958 | 2.04E-03 |
| CALU, CELF2, CERS4, EPHX2, JUN, LARGE, LTBP1, VAV3 | Cancer, Cellular Movement, Organismal Development | Supp. Fig. 7 | FOS | transcription regulator | Activation | 1.698 | 3.59E-02 |
| AEBP1, EDN1, JUN, PGK1, PTPN11, SLC25A11 | Cell Morphology, Cellular Assembly and Organization, Cellular Function and Maintenance | Supp. Figs 8 and 18 | Insulin | hormone | Activation | 1.513 | 3.02E-02 |
| EDN1, JUN, MIOX, PRDX2 | Cell To Cell Signaling and Interaction, Reproductive System Development and Function, Cell Signaling | Supp. Fig. 16 | N-acetyl-L-cysteine | chemical drug | Inhibition | −1.941 | 5.0E-02 |
| mICSI BCB− vs ICSI BCB− blastocysts | |||||||
| CCND2, EDN1, IL18, TRAF2 | Cellular Development, Cellular Growth and Proliferation, Hematological System Development and Function | Supp. Figs 8, 12, 17 and 18 | Resveratrol | Chemical drug | Activation | 1.954 | 1.19E-02 |
| CCND2, CGREF1, EDN1, IL18, TRAF2 | Cellular Development, Cellular Growth and Proliferation, Hematological System Development and Function | Supp. Figs 7, 8, 12, 17 and 18 | NFkB (complex) | Complex | Inhibition | −2.208 | 3.62E-02 |
| CCND2, LIMK2, NABP1, UPB1 | Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking | Supp. Figs 11 and 16 | IL5 | Cytokine | Inhibition | −2.000 | 9.57E-03 |
| mICSI BCB− vs ICSI BCB+blastocysts | |||||||
| ATF4, CLDN7, CYTH2, DDIT4, FTH1, LDHB, MCL1, SMN1/SMN2, TP53I3, UBE2S | Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral Metabolism | Not displayed | MYC | Transcription regulator | Activation | 2.156 | 3.13E-02 |
| AP2A2, ATF4, DPM3, LRRFIP1 | Cellular Compromise, Infectious Disease, Drug Metabolism | Supp. Fig. 7 | STAT4 | Transcription regulator | Activation | 2 | 4.01E-02 |
| ADIPOR2, FABP3, MIOX, STUB1 | Carbohydrate Metabolism, Cell Cycle, Developmental Disorder | Supp. Fig. 16 | Streptozocin | Chemical drug | Activation | 1.98 | 3.46E-02 |
DEGs were clustered according to their predicted upstream regulators based on prior knowledge of expected regulation from the Ingenuity® Knowledge Base.